RxDoctor Payments Data

Denise Deveranez, MD

Internal Medicine · Stockbridge, GANPI 1659409043

Payments from drug & device makers

$1,412in general payments, 2019–2025

Across 62 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$601
  • AstraZeneca$241
  • Lilly USA, LLC$190
  • Exact Sciences$138
  • Bayer$103
  • GSK$67
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$1,38098%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,412 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$57,669
Medicare patients
139
Services billed
731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$262,732
TrulicityDulaglutide25$61,606
MounjaroTirzepatide20$35,221
FarxigaDapagliflozin Propanediol25$29,444
JardianceEmpagliflozin16$19,121
EliquisApixaban24$18,314
JanuviaSitagliptin Phosphate14$14,381
VascepaIcosapent Ethyl19$12,544
Victoza 3-PakLiraglutide12$9,200
Duloxetine Hcl269$8,836
Diclofenac Sodium42$6,937
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid31$6,231
Rosuvastatin Calcium584$6,071
Albuterol Sulfate HfaAlbuterol Sulfate77$3,427
Gabapentin145$2,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$601$262,732152 claims
Lilly USA, LLCTrulicity, Mounjaro$190$96,82645 claims
AstraZenecaFarxiga$241$29,44425 claims
PfizerEliquis$33$18,31424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →